A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Researchers assessed the efficacy of aflibercept 8 mg vs conventional 2 mg doses at 96 weeks in patients with diabetic ...

Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an ...

CHICAGO, CA, UNITED STATES, October 18, 2024 /EINPresswire / -- The Global Age-Related Macular Degeneration (AMD) <a target=_blank href= ...

The most pressing challenges include the financial and emotional burdens associated with frequent, long-term treatments for ...

The global Retinal Vein Occlusion (RVO) treatment market was valued at approximately USD 2.65 billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 6.92% over the ...

Adalimumab biosimilar market shares have steadily increased, but challenges remain due to pricing strategies and limited government support, according to the Samsung Bioepis report.

The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head ...